Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?

AIDS

Volumn 21, Issue 12, 2007, Pages 1651-1653

  Hill, Andrew ^a   Miralles, Diego ^b   Vangeneugden, Tony ^b   Lefebvre, Eric ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Virco BVBA   (Belgium)

^c Janssen Cilag BV Netherlands   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; ENFUVIRTIDE; MARAVIROC; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR; VIRUS RNA;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; GENE REPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34447523839     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282703593     Document Type: Article

References (18)

1. Murray JS, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999; 13:797-804.
2. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen D, et al. Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society - USA Panel. JAMA 2006; 296:827-843.
3. Cooper D, Gatell J, Rockstroh J, Katlama C, Yeni P, Lazzarin A, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, 25-28 February 2007. Abstract 105aLB.
4. Steigbegel R, Kumar P, Eron J, Schechter M, Markowitz M, Loufty M, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, 25-28 February 2007. Abstract 105bLB.
5. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, Trottier B, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348:2175-2185.
6. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al. Efficacy of enfuvirtide in patients infected with drug-resistant human immunodeficiency virus type 1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195.
7. Nelson M, Arasteh K, Clotet B, Cooper D, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005; 40:404-411.
8. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475.
9. Clotet B, Bellos N, Molina J, Cooper D, Goffard J, Lazzarin A, et al. Efficacy and safety of darunavir/r in treatment experienced patients: week 48 results of POWER 1 and 2. Lancet 2007; 369:1169-1178.
10. Nelson M, Fatkenheuer G, Konourina I, Lazzarin A, Clumeck N, Horban A, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, 25-28 February 2007. Abstract 104aLB.
11. Lalezari J, Goodrich J, DeJesus E, Lampiris H, Gulick R, Saag M, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. In: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, USA, 25-28 February 2007. Abstract 104bLB.
12. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-694.
13. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med 2003; 139:313-320.
14. GlaxoSmithKline, Inc. Lexiva (fosamprenavir) US prescribing information. June 2006. Available at: http://www.lexiva.com; Accessed: 3 October 2006.
15. Hill A, DeMasi R. Discordant conclusions from HIV clinical trials - an evaluation of efficacy endpoints. Antivir Ther 2005; 10:367-374.
16. Ledergerber B, Lundgren J, Walker A, Sabin C, Justice A, Reiss P, et al. Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364:51-62.
17. Benzie A, Bansi L, Sabin C, Walsh J, Phillips A. Viral rebound in patients on HAART with viral suppression. BHIVA Spring Conference, Brighton, UK, April 2006. HIV Med 2006; 7 (Suppl. 1):1-9; Abstract O9.
18. Cozzi-Lepri A, Phillips A, Ruiz L, Clotet B, Loveday C, Kjaer J, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-732.